About Thyssen Biopharmaceuticals
Thyssen Biopharmaceuticals is a company based in Pohang-si (South Korea) founded in 2021.. Thyssen Biopharmaceuticals has raised $1.59 million across 1 funding round from investors including Envisioning Partners, Stonebridge Ventures and FuturePlay. Thyssen Biopharmaceuticals offers products and services including Cell-Grown Meat. Thyssen Biopharmaceuticals operates in a competitive market with competitors including Simple Planet, HN Novatech, Innohas, DaNAgreen and SEAWITH, among others.
- Headquarter Pohang-si, South Korea
-
Sectors
Consumer
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$1.59 M (USD)
in 1 rounds
-
Latest Funding Round
$1.59 M (USD), Seed
Sep 19, 2022
-
Investors
Envisioning Partners
& 3 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Thyssen Biopharmaceuticals
Thyssen Biopharmaceuticals offers a comprehensive portfolio of products and services, including Cell-Grown Meat. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Sustainable meat produced by cultivating animal cells without farming.
Funding Insights of Thyssen Biopharmaceuticals
Thyssen Biopharmaceuticals has successfully raised a total of $1.59M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.59 million completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Seed — $1.6M
-
First Round
First Round
(19 Sep 2022)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2022 | Amount | Seed - Thyssen Biopharmaceuticals | Valuation | Envisioning Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Thyssen Biopharmaceuticals
Thyssen Biopharmaceuticals has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Envisioning Partners, Stonebridge Ventures and FuturePlay. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
No specific activity is described for this entity.
|
Founded Year | Domain | Location | |
|
Venture capital investments in technology and AI sectors are provided.
|
Founded Year | Domain | Location | |
|
FuturePlay is engaged in startup investment and acceleration.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Thyssen Biopharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Thyssen Biopharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Thyssen Biopharmaceuticals Comparisons
Competitors of Thyssen Biopharmaceuticals
Thyssen Biopharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Simple Planet, HN Novatech, Innohas, DaNAgreen and SEAWITH, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Provider of plant-based cultivated meat
|
|
| domain | founded_year | HQ Location |
Platform offering alternative meat products
|
|
| domain | founded_year | HQ Location |
Plant-based meat substitute novel food products are developed by Innohas.
|
|
| domain | founded_year | HQ Location |
Provider of scaffolds to culture cells in 3D
|
|
| domain | founded_year | HQ Location |
Cultured meat products are developed from seaweed using lab-based methods.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Thyssen Biopharmaceuticals
When was Thyssen Biopharmaceuticals founded?
Thyssen Biopharmaceuticals was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Where is Thyssen Biopharmaceuticals located?
Thyssen Biopharmaceuticals is headquartered in Pohang-si, South Korea. It is registered at Pohang-si, North Gyeongsang Province, South Korea.
Who is the current CEO of Thyssen Biopharmaceuticals?
Wonil Han is the current CEO of Thyssen Biopharmaceuticals.
Is Thyssen Biopharmaceuticals a funded company?
Thyssen Biopharmaceuticals is a funded company, having raised a total of $1.59M across 1 funding round to date. The company's 1st funding round was a Seed of $1.59M, raised on Sep 19, 2022.
What does Thyssen Biopharmaceuticals do?
Thyssen Biopharmaceuticals was established in 2021 as a biopharmaceutical entity. An online platform is maintained to distribute lab-grown meat substitutes produced through tissue engineering. Cultivated meat is manufactured in kilogram quantities, featuring realistic texture and marbling. Artificial organs for medical applications are also developed using similar technologies. Operations center on innovations in food alternatives and regenerative medicine, with details on geographic presence unavailable.
Who are the top competitors of Thyssen Biopharmaceuticals?
Thyssen Biopharmaceuticals's top competitors include Simple Planet, DaNAgreen and HN Novatech.
What products or services does Thyssen Biopharmaceuticals offer?
Thyssen Biopharmaceuticals offers Cell-Grown Meat.
Who are Thyssen Biopharmaceuticals's investors?
Thyssen Biopharmaceuticals has 4 investors. Key investors include Envisioning Partners, Stonebridge Ventures, FuturePlay, and Mirae Holdings.